Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients

Multiple Sclerosis : Clinical and Laboratory Research
Elizabeth A Mills, Yang Mao-Draayer

Abstract

New potent immunomodulatory therapies for multiple sclerosis (MS) are associated with increased risk for progressive multifocal leukoencephalopathy (PML). It is unclear why a subset of treated patients develops PML, but patient age has emerged as an important risk factor. PML is caused by the JC virus and aging is associated with immune senescence, which increases susceptibility to infection. With the goal of improving PML risk stratification, we here describe the lymphocyte changes that occur with disease-modifying therapies (DMTs) associated with high or moderate risk toward PML in MS patients, how these changes compare to immune aging, and which measures best correlate with risk. We reviewed studies examining how these therapies alter patient immune profiles, which revealed the induction of changes to lymphocyte number and/or function that resemble immunosenescence. Therefore, the immunosuppressive activity of these MS DMTs may be enhanced in the context of an immune system that is already exhibiting features of senescence.

References

Oct 1, 1988·Acta Neurologica Scandinavica·G L StonerH D Webster
May 8, 1997·Biochemical and Biophysical Research Communications·M VandermeerenJ Geysen
Apr 8, 1998·Journal of Neurovirology·J R BergerM Whiteman
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·A Puig-KrögerA L Corbí
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S HaiderJ Fogle
Dec 17, 2003·The Journal of Investigative Dermatology·Felix TreumerUlrich Mrowietz
Dec 22, 2004·The Journal of Experimental Medicine·Sheri M EatonLaura Haynes
Apr 25, 2006·Annals of Neurology·Olaf StüveMichael K Racke
Aug 15, 2006·Journal of Neuroimmunology·Anne H CrossJeri-Anne Lyons
Nov 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Magali M MorettoImtiaz A Khan
May 16, 2009·Cancer Immunology, Immunotherapy : CII·Yu Cheng TangAlbert Deisseroth
Apr 28, 2010·Immunity & Ageing : I & a·Christine V CrooksClare R Wall
Aug 24, 2010·Ageing Research Reviews·Daniela FrascaBonnie B Blomberg
Oct 30, 2010·Nature Reviews. Drug Discovery·Volker BrinkmannPascale Burtin
Apr 22, 2011·Journal of Virology·Cristina P MarquesCornelia C Bergmann
Jun 10, 2011·Current Opinion in Immunology·Marcia A Blackman, David L Woodland
Jun 30, 2011·Immunology·Marius StriogaDainius Characiejus
Sep 13, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Nicholas SchwabHeinz Wiendl
Nov 8, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·Grant A Hill-CawthorneAlasdair J Coles
Dec 14, 2011·Proceedings of the National Academy of Sciences of the United States of America·Rachael D AubertRafi Ahmed
Mar 1, 2012·Age·Pierre Olivier LangRichard Aspinall
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic
Dec 12, 2012·PloS One·Lars BörnsenFinn Sellebjerg
Mar 6, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Tomas OlssonDorothea Buck
May 8, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Laura D SerperoDaniela Fenoglio
Jun 7, 2013·The New England Journal of Medicine·Eugene O MajorDaniel Douek
Jun 14, 2013·Journal of Neuroimmunology·Michael J TurnerWilliam M Siders
Aug 9, 2013·Neurology·Claire L McCarthyJoanne L Jones
Nov 15, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bo-Chin ChiuStephen W Chensue

❮ Previous
Next ❯

Citations

Jun 5, 2019·Continuum : Lifelong Learning in Neurology·Robert H Gross, John R Corboy
Jan 24, 2020·Expert Review of Neurotherapeutics·Aurora ZanghìFrancesco Patti
Mar 13, 2019·Neurology. Clinical Practice·Edward J FoxAaron Boster
Feb 29, 2020·Cells·Itay RaphaelThomas G Forsthuber
Jul 21, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Jeanne GarciaBruno Stankoff
Aug 19, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Allison Lm JordanYang Mao-Draayer
Apr 10, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Simonetta GereviniLuisa Imberti
Dec 5, 2020·Multiple Sclerosis and Related Disorders·Le H HuaKathryn C Fitzgerald
Jul 21, 2020·Journal of Neuroimmunology·Maria Rosa CiardiClaudio Maria Mastroianni
Apr 6, 2021·Frontiers in Neurology·Riley BoveEva Kubala Havrdová
May 26, 2021·La Presse médicale·Ilaria CallegariEdoardo Galli
Aug 26, 2021·Neurology. Neuroimmunology and Neuroinflammation·Ryotaro IkeguchiKazuo Kitagawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Eric M L Williamson, Joseph Berger
Multiple Sclerosis and Related Disorders
Joseph Berger
Therapeutic Advances in Neurological Disorders
Dejan PavlovicProgressive Multifocal Leukeoncephalopathy Consortium
© 2022 Meta ULC. All rights reserved